Combination treatment for advanced nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests a combination of three drugs (chidamide, toripalimab, and anlotinib) for people with nasopharyngeal cancer that has spread or come back. The goal is to see if this combination can help control the cancer when other treatments have not worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have nasopharyngeal cancer that has spread or returned after at least one prior treatment.
- You are in generally good health (able to do light activities).
- You have at least one tumor that can be measured on scans.
- If you've had immunotherapy before, it worked for at least 6 months and you've only had one type.
- Your blood, liver, kidney, and thyroid function are within acceptable levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment plan for a specific type of advanced nasopharyngeal cancer. It combines chemotherapy and radiation to see if it can improve outcomes for people with high-risk stage III disease.
This trial tests a combination of two types of radiation therapy (standard SBRT and low-dose radiation) along with chemotherapy and an immunotherapy drug (PD-1 antibody) for people whose nasopharyngeal cancer has come back or spread. The goal is to see if this combination can better control the cancer.
This trial tests a new treatment for advanced nasopharyngeal cancer. You will get chemotherapy and radiation, followed by maintenance therapy with an immunotherapy drug called toripalimab to help your immune system fight the cancer.
This trial studies whether adding an anti–PD-1 immunotherapy to standard chemoradiotherapy can control nasopharyngeal cancer that has come back in the local area. It may help patients live longer or have the cancer respond better compared with chemoradiotherapy alone.
This trial tests a new combination of drugs and radiation for advanced nasopharyngeal cancer. It aims to improve outcomes by adding a type of immunotherapy and an omega-3 supplement to standard treatment.
This trial tests a new combination of chemotherapy and immunotherapy drugs for advanced nasopharyngeal cancer that has not spread to distant parts of the body. The goal is to see if this approach works better than standard treatment.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.